Biotech IPO Investor Guide
Most biotech IPOs underperform. The ones that don't are picked using a different framework than "the next Moderna". Here's it.
Start free with Clinical Investor âBiotech IPOs are sold to retail investors as moonshots, but the data shows about 60% trade below their offer price within 12 months. The winners follow recognizable patterns. The losers also follow recognizable patterns. Here's how to tell them apart.
What a biotech IPO actually is
A biotech IPO is a company raising capital by selling new shares to public investors. For most biotechs, the IPO happens at Phase 1 or Phase 2 stage â well before any approved drug or revenue. The company is selling future potential.
- Capital raised: Typically $50M-$300M (small-mid cap biotech)
- Lockup period: 90-180 days during which insiders can't sell
- Float: Often only 15-25% of outstanding shares (rest held by insiders, VCs)
- Post-lockup pressure: When lockup expires, insider selling often pushes prices down 20-40%
How to evaluate an IPO prospectus (S-1)
- Read the "Risk Factors" section first. What the company is required to disclose tells you what they're worried about.
- Check the lead asset's clinical stage and data. Phase 1 IPOs are essentially venture investments. Phase 2 with positive data is the sweet spot.
- Use of proceeds. "Funding ongoing trials" is good; "general corporate purposes" is vague.
- Cash runway post-IPO. Cash + IPO proceeds ÷ quarterly burn = months of runway. Less than 18 months = expect dilution.
- Tier of underwriters. Goldman Sachs, JPMorgan, Morgan Stanley = signals stronger institutional interest. Smaller underwriters = harder to sell secondary.
- Prior funding rounds. Has the company raised at increasing valuations? Are top-tier VCs invested?
When to buy a biotech IPO
- Don't buy at IPO unless you have allocation and high conviction. Most retail can't get allocation; buying at the open often means paying a 30-100% premium to IPO price.
- Wait 6 months for lockup expiration. Insider selling pressure typically pushes prices down 20-40%. That's often the best entry point IF the underlying thesis is intact.
- Monitor for catalyst alignment. If a Phase 2 readout is expected within 12 months of IPO, position before the catalyst, not at IPO pricing.
Red flags in biotech IPOs
- Multiple management changes during the IPO process
- Lead asset is in-licensed from a foreign parent (limits long-term value)
- Filing in Q4 with rushed timeline (often capital-need-driven)
- "Pivoted" from a different therapeutic area pre-IPO
- Pre-IPO valuation jumped significantly without intervening data
Get the catalyst calendar + Trial Translator
Free tier: weekly catalyst briefing, basic company profiles. Premium ($19/mo): real-time alerts, unlimited Trial Translator, deep dives.
Start free âFrequently Asked Questions
- Can I buy at the IPO price?
- Usually only with significant brokerage relationships and account size. Retail investors typically buy on the open after IPO, which means paying premium to the IPO price.
- What's a typical biotech IPO success rate?
- About 40% of biotech IPOs trade above their offer price 12 months later. About 60% are below. The winners can be 5-10x; losers can be down 70-90%.
- When should I sell a biotech IPO position?
- Sell when (a) thesis is invalidated by data, (b) lockup expiration is imminent and you need to free capital, (c) the position grew too large.
- Are biotech IPOs riskier than other IPOs?
- Yes â most biotech IPOs are pre-revenue and pre-approval, so they're effectively venture-stage investments traded publicly. Variance is much higher than tech or consumer IPOs.
Related guides
Educational only. Not investment advice. Biotech investing carries substantial risk; consult a licensed advisor.